

Retriever Medical Announces Notice of Allowance for Innovative Occlusion Device

Retriever Medical's innovative occlusion device for anatomical passageways has received Notice of Allowance, marking a major milestone in vascular technology.


LAS VEGAS, NV, UNITED STATES, September 10, 2024 /EINPresswire.com/ -- [Retriever Medical](#), a leader in medical device innovation, is thrilled to announce that the United States Patent and Trademark Office (USPTO) has officially issued a Notice of Allowance for [U.S. Application No. 17/809,528](#). This patent application covers a groundbreaking device designed for occluding anatomical passageways between structures, marking a significant advancement in medical device technology.

The patented technology promises to revolutionize the treatment of atrial septal defects and other anatomical passages. The device features a handle coupled to a tip portion via a first member, with a proximal element, a distal element, and a second member extending between them.

The key innovation allows the proximal element to move axially along the second member while the distal element remains fixed. Both elements can expand from a linear configuration to a three-dimensional geometric shape, precisely sealing anatomical passages.

Key Features and Advantages of the Patented Device:


- **Expandable Elements:** Proximal and distal elements can expand from a linear configuration to a significantly larger three-dimensional shape, enhancing occlusion effectiveness.
- **Controlled Deployment:** The device includes a handle with interfaces for precise control of the device's deployment and detachment, ensuring reliable placement and occlusion.



- **Locking Mechanism:** A unique locking device secures the device in place after deployment, with options for mechanical, electrolytic, or thermal release.
- **Hydrogel Coating:** Some elements are coated with hydrogel to assist in sealing and to adapt to anatomical passageways, improving effectiveness and patient outcomes.
- **Versatile Use:** The device can be employed for a range of anatomical passages and puncture sites, offering a significant improvement over conventional closure methods.

Additionally, the technology encompasses a thrombectomy system with a unique sensor for monitoring the pressure exerted on vessel walls by the expandable elements. This advancement ensures better control and minimizes complications related to conventional methods.

"The issuance of the Notice of Allowance is a significant endorsement of our efforts to revolutionize the treatment of vascular diseases. At Retriever Medical, we are driven by our mission to deliver innovative solutions that not only advance medical practice but also lead to better patient outcomes. We are excited to continue our journey with this innovative vascular approach," said Ben Bobo, CEO of Retriever Medical.



“

The issuance of the Notice of Allowance is a significant endorsement of our efforts to revolutionize the treatment of vascular diseases.”

Ben Bobo

This Notice of Allowance highlights Retriever Medical's commitment to advancing medical technology and providing innovative solutions for challenging medical conditions. The approval reflects the device's potential to address critical needs in the medical field and improve patient care outcomes.

About Retriever Medical

Retriever Medical is a cutting-edge medical device company dedicated to developing innovative solutions for the treatment of vascular diseases. With a focus on mechanical thrombectomy, the company's portfolio includes state-of-the-art devices designed to improve patient outcomes by providing physicians with advanced tools for the removal of blood clots. Retriever Medical is committed to advancing the field of interventional medicine through continued innovation and collaboration with leading healthcare

professionals.

Ben Bobo

Retriever Medical, Inc.


+1 7146542367

[email us here](#)

Visit us on social media:

[X](#)

[LinkedIn](#)



Deployed discs effectively closing the atrial septal defect.

This press release can be viewed online at: <https://www.einpresswire.com/article/741371313>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.